Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

From Genes To Drugs: Targeted Strategies For Melanoma

K. Flaherty, F. S. Hodi, D. Fisher
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
The past decade has revealed that melanoma is comprised of multiple subclasses that can be categorized on the basis of key features, including the clinical stage of disease, the oncogenic molecular 'drivers', the anatomical location or the behaviour of the primary lesion and the expression of specific biomarkers. Although exercises in subclassification are not new in oncology, progress in this area has produced both conceptual and clinical breakthroughs, which, for melanoma, are unprecedented in the modern history of the disease. This Review focuses on these recent striking advances in the strategy of molecularly targeted approaches to the therapy of melanoma in humans.
This paper references
Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control
D. W. Mullins (2003)
Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Y. Wang (1996)
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
C. Slingluff (2003)
J. Du (2002)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
B. Davies (2007)
Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors
J. Webster (2005)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
R. Vonderheide (2007)
Phase II trial of 17-allylamino17-demethoxygeldanamycin in patients with metastatic melanoma
Solit (2008)
Expression of interleukin‐8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma
W. Nürnberg (1999)
Expression of platelet‐derived growth factor (PDGF)‐A, PDGF‐B and the PDGF‐alpha receptor, but not the PDGF‐beta receptor, in human malignant melanoma in vivo
R. Barnhill (1996)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
G. Hatzivassiliou (2010)
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
J. Banchereau (2001)
The central role of CD4+ T cells in the antitumor immune response
K Hung (1998)
Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
J. Young (1996)
Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.
L. Ferradini (1993)
RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
P. Poulikakos (2010)
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
V. K. Goel (2006)
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104.
T. Gajewski (2006)
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
R. Soiffer (2003)
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
T. Wolfel (1995)
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
A. Hauschild (2008)
Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
G. Yang (2005)
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma.
F. Meier (2005)
A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
Robbins (1996)
The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Peng Xie (2009)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
An oncogenic role for ETV1 in melanoma.
J. Jané-Valbuena (2010)
Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability
G. McGill (2002)
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
B. J. Van den Eynde (1995)
implications for normal physiology, malignant transformation, and cancer therapy
Sebti (2005)
The Central Role of CD4+ T Cells in the Antitumor Immune Response
K. Hung (1998)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
P. O'dwyer (2007)
[Recent findings in ].
Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells
B. Schuler-Thurner (2002)
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
I. Weinstein (2006)
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF.
Jinyan Du (2004)
Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia
Price (1998)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
A. Mccullough (2013)
Characterization of mutagen-activated cellular oncogenes that confer anchorage independence to human fibroblasts and tumorigenicity to NIH 3T3 cells: sequence analysis of an enzymatically amplified mutant HRAS allele.
C. W. Stevens (1988)
Presence on a human melanoma of multiple antigens recognized by autologous CTL
B. Den Van Eynde (1989)
CD4+CD25+ T Regulatory Cells Dependent on ICOS Promote Regulation of Effector Cells in the Prediabetic Lesion
A. Herman (2004)
Tumor‐specific shared antigenic peptides recognized by human T cells
P. van der Bruggen (2002)
NKT cells - conductors of tumor immunity?
M. Smyth (2002)
New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells.
Byungsuk Kwon (2002)
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T. Eisen (2006)
Dendritic cells: a journey from laboratory to clinic
V. Cerundolo (2004)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
H. Tsao (2004)
AZD 6244 ( ARRY - 142886 ) vs temozolomide ( TMZ ) in patients ( pts ) with advanced melanoma : an open - label , randomized , multicenter , phase II study
R. Dummer (2008)
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
S. Rosenberg (1998)
beyond CD8+ T cells
B. Kwon (2002)
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
K. S. Smalley (2008)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
A. Hauschild (2009)
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
P. Robbins (1996)
BRafV600E cooperates with Pten silencing to elicit metastatic melanoma
D. Dankort (2009)
V599EB-RAF is an Oncogene in Melanocytes
C. Wellbrock (2004)
A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer
P. LoRusso (2005)
Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation?
M. Corominas (1989)
Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.
Cynthia A Chambers (1997)
Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431)
S. R. Moore (2008)
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study.
R. Dummer (2008)
Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations
T. Soussi (2005)
DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
J. Schultze (2004)
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
J. Stahl (2004)
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
V. Brichard (1993)
role in melanoma aggressiveness
Topczewska (2006)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Major response to imatinib mesylate in KIT-mutated melanoma.
F. S. Hodi (2008)
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells
M. Eskandarpour (2005)
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
E. Rofstad (2000)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
P. Poulikakos (2011)
Immunological detection of altered signaling molecules involved in melanoma development
Y. Kawakami (2005)
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
T. Gajewski (2012)
an open-label, randomized, multicenter, phase II study
Dummer (2008)
Immune Responses in 4-1BB (CD137)-Deficient Mice1
B. Kwon (2002)
CALGB 500104
Gajewski (2006)
Genetically modified tumor cell vaccines.
F. S. Hodi (1998)
CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy
U. Keilholz (2008)
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Y. Kawakami (1994)
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
F. Kabbinavar (2003)
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
R. Soiffer (1998)
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
C. Thallinger (2007)
PTEN signaling pathways in melanoma
Heng Wu (2003)
Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
J. Chernoff (2011)
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
L. Fong (2008)
Mutations of the BRAF gene in human cancer
Helen Davies (2002)
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
Kerrington R. Molhoek (2005)
TNF/TNFR family members in costimulation of T cell responses.
T. Watts (2005)
New tumor antigens recognized by T cells.
B. J. Van den Eynde (1995)
MITF pathway mutations in melanoma
S. Yokoyama (2009)
Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
J. Lutzky (2008)
Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.
M. Lens (2008)
Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.
J. Dannull (2005)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. Harbour (2010)
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
P. van der Bruggen (1991)
the role of reactive oxygen species
S. Kusmartsev (2003)
Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells.
Y. Yuasa (1984)
Rapid induction of tumorspecific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells
B Schuler-Thurner (2002)
comparison of prophylaxis and therapy
van Elsas (2001)
Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients
D. H. Chang (2005)
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
S. Yokoyama (2008)
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
J. Guo (2011)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
S. Shangary (2008)
c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.
M. Wu (2000)
a randomised, double-blind, multicentre, phase 2, doseranging study
Wolchok (2010)
Bcl 2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma
G. G. McGill
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
Levi A. Garraway (2005)
MITF: master regulator of melanocyte development and melanoma oncogene.
C. Levy (2006)
Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study
J. Fruehauf (2008)
A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma
Kimberly A. Varker (2007)
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Z. Shen (1997)
Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli
Alireza Alavi (2003)
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma
D Dankort (2009)
the active ingredient in bacterial extracts? Nature Med
Krieg (2003)
dendritic cellbased vaccine in the treatment of patients with advanced melanoma
S. Zhang (2007)
CCI‐779 in metastatic melanoma
K. Margolin (2004)
Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
A. Potti (2003)
A novel transforming gene in a human malignant melanoma cell line
R. Padua (1984)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
S. O’Day (2010)
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
A. Huang (1994)
A cell cycle regulator potentially involved in genesis of many tumor types.
A. Kamb (1994)
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
S. Ugurel (2001)
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
K. S. Smalley (2007)
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma
S. Yokoyama (2011)
Distinct sets of genetic alterations in melanoma.
J. A. Curtin (2005)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm (2006)
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
S. O’Day (2007)
Model predicting survival in stage I melanoma based on tumor progression.
W. Clark (1989)
CpG motifs: the active ingredient in bacterial extracts?
Arthur M Krieg (2003)
Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference
H. Sumimoto (2004)
In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
K. Yao (2005)
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
K. Margolin (2004)
Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells.
M. Romano (2004)
A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer.
M. Martín (2009)
BRAF mutation predicts sensitivity to MEK inhibition
D. Solit (2006)
Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild‐type INK4A in melanoma cells
Sabrina Rotolo (2005)
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
P. Coulie (1994)
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Jessie Villanueva (2010)
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
J. Wolchok (2008)
Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma
M. Bendandi (1999)
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J. Shimizu (1999)
New insight into BRAF mutations in cancer.
N. Dhomen (2007)
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness
J. Topczewska (2006)
[Phase II study].
H. Niitani (1995)
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
R. Kefford (2010)
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
A. van Elsas (2001)
HOXB7 constitutively activates basic fibroblast growth factor in melanomas.
A. Carè (1996)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C. Michaloglou (2005)
Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells
J. Fay (2005)
KIT as a therapeutic target in metastatic melanoma.
R. Carvajal (2011)
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
L. J. van 't Veer (1989)
BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells
E. Sala (2008)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
C. Emery (2009)
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species
S. Kusmartsev (2003)
Amplification of CDK4 and MDM2 in malignant melanoma
Viswanathan Muthusamy (2006)
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
M. Stark (2007)
Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB.
K. Forsberg (1993)
Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H. Shi (2012)
Somatic activation of KIT in distinct subtypes of melanoma.
J. A. Curtin (2006)
Review: dendritic cell-based vaccine in the treatment of patients with advanced melanoma.
S. Zhang (2007)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
P. Chapman (2011)
Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43–9006 alone in patients with metastatic melanoma
K. Flaherty (2005)
A translational bridge to cancer immunotherapy
R. Vonderheide (2003)
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
N. Mach (2000)
Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases
G. Krähn (2001)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
S. Heidorn (2010)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Yoshiko Iwai (2002)
Suppression of BRAF(V599E) in human melanoma abrogates transformation.
S. Hingorani (2003)
Oncogenic Braf induces melanocyte senescence and melanoma in mice.
N. Dhomen (2009)
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
Y. Kawakami (1994)
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
T. Prickett (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
T. Milman (2010)
New insights into the role of 4 – 1 BB in immune responses : beyond CD 8 + T cells
B. S. Kwon (2002)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
C. Beadling (2008)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
X. Jiang (2008)
Frequent p16-independent inactivation of p14ARF in human melanoma.
D. Freedberg (2008)
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
R. Nazarian (2010)
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
A. J. King (2006)
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
D. Solit (2008)
is HRAS involved in differentiation as well as proliferation? Proc
M. Corominas (1989)
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
P. Coulie (2002)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
J. Tsai (2008)
a novel strategy for the treatment of melanoma and other malignancies
S. J. O’Day (2007)
negative regulator of the immune response and a target for cancer therapy
Keilholz (2008)
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
C. Bertolotto (2011)
Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
Z. Su (2003)
Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells
M. Dhodapkar (2001)
Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.
J. Reed (1994)
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
K. Paraiso (2011)
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization.
B. Bastian (1998)
A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors.
G. Schwartz (2009)
Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).
M. Ratain (2004)
Inhibition of mutated, activated BRAF in metastatic melanoma.
K. Flaherty (2010)
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation
P. Gupta (2005)
B-RAF is a therapeutic target in melanoma
M. Karasarides (2004)
Peptide-Based Cancer Vaccines
RK Bright (2002)
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
G. Dranoff (1993)
BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma
E. Patton (2005)
Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.
S. Sebti (2005)
BRAF alterations are associated with complex mutational profiles in malignant melanoma
M. Daniotti (2004)
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
S. Wilhelm (2004)
Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression.
O. Straume (2002)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
K. S. Smalley (2008)
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
K. S. Smalley (2009)
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
P. Guldberg (1997)
Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation.
P. Srivastava (1993)
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.
J. Infante (2010)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
M. Middleton (2000)
exploiting costimulation and target antigens for active and passive T cell immunotherapy
R. H. Vonderheide (2003)
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
L. Fong (2001)
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
Silvy da Rocha Dias (2005)
CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models
E. Venetsanakos (2006)
PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells.
G. Cai (2004)
The GIST paradigm: lessons for other kinase‐driven cancers
C. Antonescu (2011)
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH
G. Jönsson (2007)
Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF
C. Wellbrock (2008)
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
Y. Kawakami (1994)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)

This paper is referenced by
Eradicating tumor drug resistance at its YAP‐biomechanical roots
Francesca Zanconato (2016)
[Diagnosis of brain metastases: an update in 2012].
E. Lechapt-Zalcman (2013)
Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells
M. Humar (2014)
Activation of Wnt/β-Catenin Signaling Increases Apoptosis in Melanoma Cells Treated with Trail
Z. F. Zimmerman (2013)
UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis.
L. Wurth (2016)
Current status of diagnostic and prognostic markers in melanoma.
D. Levine (2014)
Mutations in ERBB4 may have a minor role in melanoma pathogenesis.
A. Manca (2013)
The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities
S. Sarasamma (2018)
BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells
P. Gorniak (2020)
Melanoma: oncogenic drivers and the immune system.
N. Karachaliou (2015)
Overexpression of CTHRC 1 in human melanoma promotes tumorigenesis targeted by miRNA 155
Y. Li (2017)
Expression of kit ligand and insulin-like growth factor binding protein 3 during in vivo or in vitro development of ovarian follicles in sheep.
D. Srividya (2017)
Integrated proteomic and transcriptomic analysis reveals that polymorphic shell colors vary with melanin synthesis in Bellamya purificata snail.
Songqian Huang (2020)
Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging
A. Shah (2017)
Genes and signaling pathways affecting the pathogenesis of melanoma
B. Varughese (2013)
Cell Cycle and Senescence Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identi fi es a Link Between p 14 ARF and RAR b Signaling
C. Dahl (2013)
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
J. Anastas (2014)
Focal adhesion disassembly is regulated by a RIAM to MEK-1 pathway
G. Coló (2012)
Aberrant expression of kallikrein‐related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion
Tiphaine Delaunay (2017)
ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Ueihuei Peng (2017)
Malignant melanoma and melanocortin 1 receptor
A. A. Rosenkranz (2013)
Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF.
S. Giroux (2013)
Avaliação da atividade citotóxica e melanogênica do complexo de platina (II) com derivado de hidantoína em melanoma
F. Filippin (2013)
Genetic Determinants of Disease Persistence and Overt Off-Target Resistance to TKI therapy in Chronic Myeloid Leukemia
Gabriel A. Reyes (2014)
Anti-melanoma effects and mechanism of action of a herbal formula comprising Sophorae flos and Lonicerae Japonicae flos
T. Li (2017)
Lack of SF3B1 R625 mutations in cutaneous melanoma
B. Schilling (2013)
Recent advances in targeted nanoparticles drug delivery to melanoma.
J. Li (2015)
Oncogenes in melanoma: an update.
M. Kunz (2014)
Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies
Robin Didier (2018)
Functional Profiling of Live Melanoma Samples Using a Novel Automated Platform
Adam Schayowitz (2012)
Systematic approaches to overcoming limitations of MAPK pathway inhibition in melanoma
David J. Konieczkowski (2013)
RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells
Nouar Qutob (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar